Do Analysts Think Eyenovia Inc (EYEN) Is Still Worth Buying In 2024?

Eyenovia Inc (NASDAQ:EYEN) does about 1.75M shares in volume on a normal day but saw 762519 shares change hands in the recent trading day. The company now has a market cap of 39.08M USD. Its current market price is $0.51, marking a decrease of -4.90% compared to the previous close of $0.53. The 52 week high reached by this stock is $2.57 whilst the lowest price level in 52 weeks is $0.37.

Eyenovia Inc (EYEN) has a 20-day trading average at $0.5439 and the current price is -80.23% off the 52-week high compared with 37.32% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.8647 and its 200-day simple moving average is $1.1623. If we look at the stock’s price movements over the week, volatility stands at 7.22%, which increases to 13.44% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 36.68 to suggest the stock is neutral.

The consensus objective for the share price is $7.67, suggesting that the stock has a potential upside of 93.35% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 01, 2021 when Northland Capital initiated the stock to “Outperform” and issued a price target of $10.

The current price level is -9.19%, -41.74%, and -56.45% away from its SMA20, SMA50, and SMA200 respectively, with the EYEN price moving above the 50-day SMA on current market day. Eyenovia Inc (EYEN) stock is down -13.17% over the week and -38.78% over the past month. Its price is -75.57% year-to-date and -70.80% over the past year.

To reach the target analysts have set, the stock logically needs to grow 93.35 percent from here.

Outstanding shares total 76.91M with insiders holding 13.31% of the shares and institutional holders owning 15.26% of the company’s common stock. The company has a return on investment of -1184.92% and return on equity of -914.66%. The beta has a value of 1.75. Price to sales ratio is 1302.60.